 |
5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(phenylmethyl)-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)- (9CI) |
|---|---|
| Trade Name | |
| Orphan Indication | Malignant gliomas |
| USA Market Approval | USA |
| USA Designation Date | 2006-10-11 00:00:00 |
| Sponsor | Reata Pharmaceuticals, Inc.;1950 N. Stemmons Freeway;Dallas, Texas, 75207 |
